| scholarly article | Q13442814 |
| P2093 | author name string | Gijsbertus J Pronk | |
| Anke Klippel | |||
| Jörg Kaufmann | |||
| Klaus Giese | |||
| Hüseyin Aygün | |||
| Frank Czauderna | |||
| Melanie Fechtner | |||
| Sibylle Dames | |||
| P2860 | cites work | Stable suppression of gene expression by RNAi in mammalian cells | Q24533429 |
| Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O-methylated adenosines | Q27748024 | ||
| RNA interference is mediated by 21- and 22-nucleotide RNAs | Q27860764 | ||
| Role for a bidentate ribonuclease in the initiation step of RNA interference | Q27860832 | ||
| Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans | Q27860867 | ||
| Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells | Q27860926 | ||
| RNA interference | Q28131798 | ||
| Single-stranded antisense siRNAs guide target RNA cleavage in RNAi | Q28201784 | ||
| Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi | Q28218870 | ||
| Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate | Q28365532 | ||
| An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells | Q29547714 | ||
| ATP requirements and small interfering RNA structure in the RNA interference pathway | Q29618384 | ||
| Argonaute2, a link between genetic and biochemical analyses of RNAi | Q29618385 | ||
| Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. | Q33951914 | ||
| Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. | Q34459792 | ||
| Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy | Q35679433 | ||
| The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity | Q36745695 | ||
| Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor | Q39597818 | ||
| Tolerance for mutations and chemical modifications in a siRNA. | Q39698017 | ||
| GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation | Q40712978 | ||
| PKR--a protein kinase regulated by double-stranded RNA. | Q41647401 | ||
| Establishment and maintenance of a heterochromatin domain | Q44128134 | ||
| RNAi in human cells: basic structural and functional features of small interfering RNA. | Q44199577 | ||
| Short 5'-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. | Q52592619 | ||
| Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. | Q52600395 | ||
| Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance | Q71823724 | ||
| Metabolism of antisense oligonucleotides in rat liver homogenates | Q73289482 | ||
| Expanding small RNA interference | Q78021693 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2705-2716 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells | |
| P478 | volume | 31 |
| Q34906848 | 8-Oxoguanosine switches modulate the activity of alkylated siRNAs by controlling steric effects in the major versus minor grooves |
| Q37199509 | A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity |
| Q40290076 | A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium |
| Q45402073 | A post-synthetic approach for the synthesis of 2'-O-methyldithiomethyl-modified oligonucleotides responsive to a reducing environment |
| Q57112729 | A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A |
| Q35192409 | A single naturally occurring 2'-O-methylation converts a TLR7- and TLR8-activating RNA into a TLR8-specific ligand |
| Q40285464 | A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. |
| Q28571503 | ASPP1/2 regulate p53-dependent death of retinal ganglion cells through PUMA and Fas/CD95 activation in vivo |
| Q33613316 | Advances in Systemic siRNA Delivery |
| Q39250878 | Advances in siRNA delivery in cancer therapy |
| Q38199518 | Advances in targeted delivery of small interfering RNA using simple bioconjugates |
| Q46715836 | An ESI-MS method for characterization of native and modified oligonucleotides used for RNA interference and other biological applications |
| Q99248466 | An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves siRNA stability |
| Q37030891 | Applying small RNA molecules to the directed treatment of human diseases: realizing the potential |
| Q54633985 | Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models |
| Q38301011 | Bioconjugates for targeted delivery of therapeutic oligonucleotides |
| Q39859749 | Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf |
| Q34725471 | Branched RNA: A New Architecture for RNA Interference |
| Q35529832 | Cell-penetrating and neurotargeting dendritic siRNA nanostructures. |
| Q49408746 | Chemical Modification of the siRNA Seed Region Suppresses Off-Target Effects by Steric Hindrance to Base-Pairing with Targets |
| Q36101387 | Chemical modification of gene silencing oligonucleotides for drug discovery and development |
| Q37655882 | Chemical modification of siRNA. |
| Q36970002 | Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs |
| Q41814077 | Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum |
| Q33308712 | Chemical modification: the key to clinical application of RNA interference? |
| Q40244901 | Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. |
| Q39121566 | Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma |
| Q50061759 | Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. |
| Q39113952 | Competition for RISC binding predicts in vitro potency of siRNA. |
| Q39664198 | Comprehensive analysis of sequence-specific stability of siRNA |
| Q38768138 | Computing in mammalian cells with nucleic acid strand exchange |
| Q37217876 | Concepts in in vivo siRNA delivery for cancer therapy |
| Q37111373 | Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice |
| Q35127967 | Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification |
| Q27648323 | Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme |
| Q92755701 | Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery |
| Q55383414 | Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs. |
| Q64085262 | Current Development of siRNA Bioconjugates: From Research to the Clinic |
| Q59358386 | Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs |
| Q28235733 | Current prospects for RNA interference-based therapies |
| Q36145606 | Defining features and exploring chemical modifications to manipulate RNAa activity |
| Q35867148 | Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media |
| Q81255488 | Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents |
| Q38692510 | Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. |
| Q57077871 | Dendritische Nanostrukturen zur rezeptorvermittelten Aufnahme von siRNA in neurale Zellen |
| Q37970644 | Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration |
| Q46847636 | Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo |
| Q89910193 | Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA |
| Q47582195 | Designing Tyrosinase siRNAs by Multiple Prediction Algorithms and Evaluation of Their Anti-Melanogenic Effects |
| Q36174842 | Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering |
| Q35179033 | Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy |
| Q37277394 | Disease-causing allele-specific silencing by RNA interference |
| Q38811665 | Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs. |
| Q49850199 | Effect of Chemical Modifications on Aptamer Stability in Serum |
| Q36935389 | Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection |
| Q42046598 | Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. |
| Q34080079 | Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters |
| Q38291528 | Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes |
| Q39765698 | Effect of north bicyclo[3.1.0]hexane 2'-deoxy-pseudosugars on RNA interference: a novel class of siRNA modification. |
| Q46671810 | Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing |
| Q41159509 | Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats |
| Q33572902 | Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs |
| Q36844506 | Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes |
| Q39647908 | Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. |
| Q95780509 | Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol |
| Q37520714 | Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. |
| Q34149828 | Efficient and targeted delivery of siRNA in vivo |
| Q24806391 | Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo |
| Q54732681 | Enhancement of RNAi activity by improved siRNA duplexes. |
| Q39277700 | Enhancement of gene silencing effect and membrane permeability by Peptide-conjugated 27-nucleotide small interfering RNA. |
| Q36169056 | Epigenetic manipulation of gene expression: a toolkit for cell biologists |
| Q37665372 | Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook |
| Q34520490 | Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging |
| Q39521378 | Fluorescence cross-correlation spectroscopy reveals mechanistic insights into the effect of 2'-O-methyl modified siRNAs in living cells |
| Q45011799 | Fluorescent tag is not a reliable marker for small RNA transfection in the presence of serum |
| Q42979094 | Function and anatomy of plant siRNA pools derived from hairpin transgenes |
| Q39202309 | Functionalization of the 3'-ends of DNA and RNA strands with N-ethyl-N-coupled nucleosides: a promising approach to avoid 3'-exonuclease-catalyzed hydrolysis of therapeutic oligonucleotides. |
| Q37194010 | Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules |
| Q36658971 | Gene control of tyrosine kinase TIE2 and vascular manifestations of infections |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q33786171 | High-density lipoproteins for the systemic delivery of short interfering RNA. |
| Q35813800 | Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo |
| Q52582698 | Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. |
| Q35697443 | Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting |
| Q37775134 | Identifying HIV-1 host cell factors by genome-scale RNAi screening. |
| Q29622905 | Illuminating the silence: understanding the structure and function of small RNAs |
| Q35029184 | Improving gene silencing of siRNAs via tricyclo-DNA modification |
| Q48093995 | In Vivo siRNA Delivery and Rebound of Renal LRP2 in Mice. |
| Q25255776 | In situ fluorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5. |
| Q34365687 | In vivo activity of nuclease-resistant siRNAs |
| Q37974175 | In vivo imaging of the systemic delivery of small interfering RNA. |
| Q36044790 | In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important |
| Q42113194 | Inhibition of MDR1 expression with altritol-modified siRNAs |
| Q33778468 | Inhibition of lung tumor growth in nude mice by siRNA(CD31) targeting PECAM-1. |
| Q90184104 | Innovative approaches for cancer treatment: current perspectives and new challenges |
| Q34234252 | Interfering with disease: opportunities and roadblocks to harnessing RNA interference |
| Q42216531 | Intracellular stability of 2'-OMe-4'-thioribonucleoside modified siRNA leads to long-term RNAi effect |
| Q36540601 | Ligand-targeted delivery of therapeutic siRNA. |
| Q37273669 | Light-activated RNA interference using double-stranded siRNA precursors modified using a remarkable regiospecificity of diazo-based photolabile groups |
| Q24676555 | Light-dependent RNA interference with nucleobase-caged siRNAs |
| Q38269555 | Lipid nanoparticles for gene delivery |
| Q39183138 | Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |
| Q53640671 | Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. |
| Q24794430 | Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality |
| Q33812404 | Logic integration of mRNA signals by an RNAi-based molecular computer |
| Q39154770 | Long double-stranded multiplex siRNAs for dual genes silencing |
| Q47900211 | Loss of Drp1 function alters OPA1 processing and changes mitochondrial membrane organization |
| Q33268852 | MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity |
| Q36050495 | Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer |
| Q37213586 | Maintaining the silence: reflections on long-term RNAi |
| Q40564594 | Mechanism of three-component collision to produce ultrastable pRNA three-way junction of Phi29 DNA-packaging motor by kinetic assessment |
| Q38615221 | Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). |
| Q36103833 | Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. |
| Q39203809 | MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines |
| Q37924177 | MicroRNA replacement therapy for cancer |
| Q49664347 | MicroRNA-31-3p Is Involved in Substance P (SP)-Associated Inflammation in Human Colonic Epithelial Cells and Experimental Colitis |
| Q37135817 | MicroRNA: An emerging therapeutic target and intervention tool |
| Q28067380 | MicroRNAs in fibrosis: opportunities and challenges |
| Q27024714 | MicroRNAs in heart failure: Small molecules with major impact |
| Q35455068 | MysiRNA-designer: a workflow for efficient siRNA design |
| Q35506520 | Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells |
| Q92621471 | Noncovalent Attachment of Chemical Moieties to siRNAs Using Peptide Nucleic Acid as a Complementary Linker |
| Q37678180 | Novel RNA-based strategies for therapeutic gene silencing |
| Q37305770 | Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy |
| Q38088755 | Nucleic acid drugs in the clinic |
| Q37338992 | Nucleic acids-based therapeutics in the battle against pathogenic viruses |
| Q89224235 | Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles |
| Q51938052 | Overview of gene silencing by RNA interference. |
| Q37873825 | Personalized cancer approach: using RNA interference technology |
| Q38707859 | Photocrosslinkable, biodegradable hydrogels with controlled cell adhesivity for prolonged siRNA delivery to hMSCs to enhance their osteogenic differentiation |
| Q37012046 | Polycation-based nanoparticle delivery for improved RNA interference therapeutics. |
| Q41627339 | Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing |
| Q36557311 | Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer |
| Q28085290 | Preclinical and clinical development of siRNA-based therapeutics |
| Q33919726 | Probing the inherent stability of siRNA immobilized on nanoparticle constructs |
| Q37478933 | Progress in microRNA delivery |
| Q28255877 | Progress toward in vivo use of siRNAs-II |
| Q28297652 | Progress towards in vivo use of siRNAs |
| Q34370185 | Quantitative evaluation of siRNA delivery in vivo. |
| Q36067739 | REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury |
| Q40840939 | RISC is a 5' phosphomonoester-producing RNA endonuclease |
| Q63979733 | RNA Modifications Modulate Activation of Innate Toll-Like Receptors |
| Q92692723 | RNA Secondary Structure Motifs of the Influenza A Virus as Targets for siRNA-Mediated RNA Interference |
| Q34655478 | RNA interference against viruses: strike and counterstrike |
| Q36944914 | RNA interference and antiviral therapy. |
| Q35967287 | RNA interference as a potential tool in the treatment of leukaemia |
| Q34729434 | RNA interference for improving the outcome of islet transplantation. |
| Q42048191 | RNA interference in mammalia cells by RNA-3'-PNA chimeras |
| Q36618289 | RNA interference in pain research |
| Q37821230 | RNA interference in the clinic: challenges and future directions |
| Q40290084 | RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy |
| Q81255508 | RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics |
| Q42814264 | RNA interference induced by siRNAs modified with 4'-thioribonucleosides in cultured mammalian cells |
| Q37693985 | RNA interference using boranophosphate siRNAs: structure-activity relationships |
| Q37598112 | RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy. |
| Q34657942 | RNA interference: from basic research to therapeutic applications |
| Q36305419 | RNA knockdown as a potential therapeutic strategy in Parkinson's disease. |
| Q28066793 | RNAi Efficiency, Systemic Properties, and Novel Delivery Methods for Pest Insect Control: What We Know So Far |
| Q34204092 | RNAi and small interfering RNAs in human disease therapeutic applications |
| Q36412870 | RNAi for treating hepatitis B viral infection |
| Q37161379 | RNAi mechanisms and applications |
| Q36597924 | RNAi therapy for neurodegenerative diseases. |
| Q40150124 | Rational design and in vitro and in vivo delivery of Dicer substrate siRNA. |
| Q36914607 | Rational design of novel N-alkyl-N capped biostable RNA nanostructures for efficient long-term inhibition of gene expression |
| Q47563314 | Recent progress in oligonucleotide therapeutics: antisense to aptamers |
| Q38298230 | Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer |
| Q36835045 | Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism. |
| Q39984813 | Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus |
| Q37896464 | Research progress on siRNA delivery with nonviral carriers |
| Q36800000 | Review of the application of RNA interference technology in the pharmaceutical industry |
| Q42123815 | SMEpred workbench: A web server for predicting efficacy of chemicallymodified siRNAs |
| Q38811832 | Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. |
| Q33486742 | Sequence determinants of innate immune activation by short interfering RNAs. |
| Q33243420 | Short interfering RNA (siRNA) as a novel therapeutic |
| Q36347546 | Short-interference RNAs: becoming medicines |
| Q34517922 | SiRNA sequence model: redesign algorithm based on available genome-wide libraries |
| Q36199753 | Silence of the transcripts: RNA interference in medicine |
| Q40678796 | Silencing of Inducible Immunoproteasome Subunit Expression by Chemically Modified siRNA and shRNA. |
| Q46850564 | Silencing of mammalian genes by tetracycline-inducible shRNA expression |
| Q33578043 | Site-specific RNase A activity was dramatically reduced in serum from multiple types of cancer patients |
| Q46415504 | Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo |
| Q24537508 | Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity |
| Q38014586 | Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. |
| Q30538460 | Sniffing for gene-silencing efficiency of siRNAs in HeLa cells in comparison with that in HEK293T cells: correlation between knockdown efficiency and sustainability of sirnas revealed by FRET-based probing |
| Q39317131 | Stability study of unmodified siRNA and relevance to clinical use. |
| Q37809577 | Staying on message: design principles for controlling nonspecific responses to siRNA. |
| Q38017713 | Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers |
| Q28288535 | Strategies for silencing human disease using RNA interference |
| Q37840092 | Strategies for tumor-directed delivery of siRNA. |
| Q41449580 | Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide |
| Q28262499 | Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain |
| Q37900313 | Structural diversity repertoire of gene silencing small interfering RNAs. |
| Q37609755 | Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice |
| Q39158150 | Synthesis of ¹⁸O-labeled RNA for application to kinetic studies and imaging |
| Q37469987 | Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. |
| Q42088063 | Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. |
| Q38940506 | Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack |
| Q42577519 | Targeted delivery of siRNA. |
| Q50769086 | Targeting Promoter-Associated Noncoding RNA In Vivo. |
| Q37798766 | The Guideline of the Design and Validation of MiRNA Mimics |
| Q38382964 | The application of RNAi-based treatments for inflammatory bowel disease |
| Q39154511 | The chemical evolution of oligonucleotide therapies of clinical utility |
| Q35950928 | The design and exogenous delivery of siRNA for post-transcriptional gene silencing. |
| Q38305049 | The emerging role of miRNAs in inflammatory bowel disease: a review |
| Q36362370 | The silent treatment: siRNAs as small molecule drugs |
| Q36237868 | The therapeutic potential of RNA interference |
| Q88875071 | Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers |
| Q37434627 | Therapeutic evaluation of microRNAs by molecular imaging |
| Q38268541 | Therapeutic face of RNAi: in vivo challenges |
| Q37587437 | Therapeutic opportunities of small interfering RNA. |
| Q39221358 | Therapeutic potential of chemically modified siRNA: Recent trends |
| Q38947480 | Therapy of respiratory viral infections with intranasal siRNAs |
| Q39409767 | Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). |
| Q24793831 | Towards in vivo application of RNA interference - new toys, old problems |
| Q36184691 | Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration |
| Q28771711 | Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin |
| Q46081080 | Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs |
| Q34348958 | Unlocking the potential of the human genome with RNA interference |
| Q37945972 | Use of RNA interference to minimize ischemia reperfusion injury |
| Q37967034 | Using non-coding small RNAs to develop therapies for Huntington's disease |
| Q40385543 | Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer |
| Q39410779 | mRNA knockdown by single strand RNA is improved by chemical modifications |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q38521725 | microRNA therapies in cancer |
| Q37297709 | siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury |
| Q36740280 | siRNA targeting Hes5 augments hair cell regeneration in aminoglycoside-damaged mouse utricle |
| Q34360881 | siRNA therapeutics: big potential from small RNAs |
| Q33925270 | siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract |
| Q41881864 | siRNA-optimized Modifications for Enhanced In Vivo Activity |
| Q34310668 | siRNAs: applications in functional genomics and potential as therapeutics |
Search more.